# US 11,026,884 B2 · Methods for improving vision

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,884 B2
- Document ID: US11026884B2
- Status: Granted
- Kind: B2
- Application number: 16/253,349
- Filed: 2019-01-22
- Published: 2019-07-25
- Granted: 2021-06-08
- Earliest claimed: 2018-01-24
- Assignees: Eye Therapies LLC
- Applicants: Eye Therapies, LLC
- Inventors: Gerald Horn
- Web page: https://patentgrep.com/patent/US11026884B2

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to methods for improving night vision and visual performance in low light conditions comprising ophthalmological administration of compositions comprising low dose brimonidine and a vehicle for improved performance.

## Claims

### Claim 1

A method of improving night vision comprising administering to an eye of subject in need thereof a composition comprising from about 0.025% to about 0.050% w/v brimonidine, from about 1% to about 5% w/v of polysorbate, mannitol at about 0.1-2.0%, hydroxypropyl methyl cellulose (HPMC) at about 0.10-1.20%, NaCl at about 0.4%, BAK at about 0.01%, and boric acid at about 5 mM wherein w/v denotes weight by total volume of the composition and wherein the composition has a pH of about 7.5, wherein the improvement of night vision occurs for at least four weeks without tachyphylaxis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polysorbate is polysorbate 80.

### Claim 3 (depends on 1)

The method of claim 1, wherein administration occurs once or twice daily.

### Claim 4 (depends on 1)

The method of claim 1, wherein a pupil of the eye of the subject is reduced diameter by 0.5 millimeters or more for 6 or more hours.

### Claim 5

A method of improving eye fatigue under a luminance level below 500 candela per square meter (cd/m2) comprising administering to an eye of subject in need thereof a composition comprising from about 0.01% to about 0.05% w/v brimonidine, from about 1% to about 5% w/v of a polysorbate, mannitol 0.10-2.0%, HPMC 0.10%-1.20%, NaCl at about 0.4%, BAK at about 0.01%; boric acid at about 5 mM wherein w/v denotes weight by total volume of the composition and wherein the composition has a pH of about 7.5.

### Claim 6 (depends on 5)

The method of claim 5, wherein the luminance levels is below 10 cd/m2.

### Claim 7 (depends on 6)

The method of claim 6, wherein the luminance level is below 1X 10-3 cd/m2.

### Claim 8

A method of improving sports performance under a luminance level below 500 candelas per square meter (cd/m2) comprising administering to an eye of subject in need thereof a composition comprising from about 0.01% to about 0.05% w/v brimonidine, from about 1% to about 5% w/v of polysorbate, mannitol 0.1-2.0%, HPMC 0.10-1.20%, NaCl at about 0.4%, BAK at about 0.01%, boric acid at about 5 mM, wherein w/v denotes weight by total volume of the composition and wherein the composition has a pH of about 7.5.

### Claim 9 (depends on 8)

The method of claim 8 wherein the luminance level is below 10 cd/m2.

### Claim 10 (depends on 9)

The method of claim 9, wherein the luminance level is below 1X 10−3 cd/m2.

### Claim 11

A method of reducing eye fatigue from indoor lighting under a luminance level below 500 candelas per square meter (cd/m2) comprising administering to an eye of subject in need thereof a composition comprising from about 0.01% to about 0.05% w/v brimonidine, from about 1% to about 5% w/v of polysorbate, mannitol 0.1-2.0%, HPMC 0.10-1.20%, NaCl at about 0.4%, BAK at about 0.01%, boric acid at about 5 mM, wherein w/v denotes weight by total volume of the composition and wherein the composition has a pH of about 7.5.